Literature DB >> 33883224

Defective Epstein-Barr Virus Genomes and Atypical Viral Gene Expression in B-Cell Lines Derived from Multiple Myeloma Patients.

Fang Lu1, Kayla A Martin1, Samantha S Soldan1, Andrew V Kossenkov1, Priyankara Wickramasinghe1, Olga Vladimirova1, Alessandra De Leo1, Cindy Lin1, Yulia Nefedova1, Paul M Lieberman1.   

Abstract

Epstein-Barr virus (EBV) is a human gammaherpesvirus that is causally associated with various lymphomas and carcinomas. Although EBV is not typically associated with multiple myeloma (MM), it can be found in some B-cell lines derived from MM patients. Here, we analyzed two EBV-positive MM-patient-derived cell lines, IM9 and ARH77, and found defective viral genomes and atypical viral gene expression patterns. We performed transcriptome sequencing to characterize the viral and cellular properties of the two EBV-positive cell lines, compared to the canonical MM cell line 8226. Principal-component analyses indicated that IM9 and ARH77 clustered together and distinct from 8226. Immunological Genome Project analysis designated these cells as stem cell and bone marrow derived. IM9 and ARH77 displayed atypical viral gene expression, including leaky lytic cycle gene expression with an absence of lytic DNA amplification. Genome sequencing revealed that the EBV genomes in ARH77 contain large deletions, while IM9 has copy number losses in multiple EBV loci. Both IM9 and ARH77 showed EBV genome heterogeneity, suggesting cells harboring multiple and variant viral genomes. We identified atypical high-level expression of lytic genes BLRF1 and BLRF2. We demonstrated that short hairpin RNA (shRNA) depletion of BLRF2 altered viral and host gene expression, including a reduction in lytic gene activation and DNA amplification. These findings demonstrate that aberrant viral genomes and lytic gene expression persist in rare B cells derived from MM tumors, and they suggest that EBV may contribute to the etiology of MM. IMPORTANCE EBV is an oncogenic herpesvirus, but its mechanisms of oncogenesis are not fully understood. A role for EBV in MM has not yet been established. We analyzed EBV-positive B-cell lines derived from MM patients and found that the cells harbored defective viral genomes with aberrant viral gene expression patterns and cell gene signatures for bone marrow-derived lymphoid stem cells. These findings suggest that aberrant EBV latent infection may contribute to the etiology of MM.

Entities:  

Keywords:  BLRF2; EBV; Epstein-Barr virus; genome deletion; genome heterogeneity; multiple myeloma

Mesh:

Substances:

Year:  2021        PMID: 33883224      PMCID: PMC8315968          DOI: 10.1128/JVI.00088-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 2.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

Review 3.  The natural history of cervical HPV infection: unresolved issues.

Authors:  Ciaran B J Woodman; Stuart I Collins; Lawrence S Young
Journal:  Nat Rev Cancer       Date:  2007-01       Impact factor: 60.716

4.  Inhibition of cGAS DNA Sensing by a Herpesvirus Virion Protein.

Authors:  Jian-jun Wu; Wenwei Li; Yaming Shao; Denis Avey; Bishi Fu; Joseph Gillen; Travis Hand; Siming Ma; Xia Liu; Wendell Miley; Andreas Konrad; Frank Neipel; Michael Stürzl; Denise Whitby; Hong Li; Fanxiu Zhu
Journal:  Cell Host Microbe       Date:  2015-08-27       Impact factor: 21.023

Review 5.  Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Authors:  Ralph D Sanderson; Yang Yang
Journal:  Clin Exp Metastasis       Date:  2007-11-20       Impact factor: 5.150

6.  Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

Authors:  Gemma Kelly; Andrew Bell; Alan Rickinson
Journal:  Nat Med       Date:  2002-09-03       Impact factor: 53.440

7.  Kaposi's Sarcoma-Associated Herpesvirus Inhibitor of cGAS (KicGAS), Encoded by ORF52, Is an Abundant Tegument Protein and Is Required for Production of Infectious Progeny Viruses.

Authors:  Wenwei Li; Denis Avey; Bishi Fu; Jian-Jun Wu; Siming Ma; Xia Liu; Fanxiu Zhu
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

Review 8.  A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Authors:  Christian M Schürch; Leo Rasche; Leonie Frauenfeld; Niels Weinhold; Falko Fend
Journal:  Virchows Arch       Date:  2019-12-17       Impact factor: 4.064

9.  Structural basis underlying viral hijacking of a histone chaperone complex.

Authors:  Hongda Huang; Zhong Deng; Olga Vladimirova; Andreas Wiedmer; Fang Lu; Paul M Lieberman; Dinshaw J Patel
Journal:  Nat Commun       Date:  2016-09-01       Impact factor: 14.919

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  3 in total

Review 1.  Epstein-Barr virus and multiple sclerosis.

Authors:  Samantha S Soldan; Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2022-08-05       Impact factor: 78.297

Review 2.  Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.

Authors:  Shimaa Hassan AbdelAziz Soliman; Arturo Orlacchio; Fabio Verginelli
Journal:  Microorganisms       Date:  2021-05-30

Review 3.  Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.

Authors:  Jessica Caro; Marc Braunstein; Louis Williams; Benedetto Bruno; David Kaminetzky; Ariel Siegel; Beatrice Razzo; Serge Alfandari; Gareth J Morgan; Faith E Davies; Eileen M Boyle
Journal:  Leukemia       Date:  2022-02-02       Impact factor: 12.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.